CytRx Submits Response To FDA Related To Clinical Program With Arimoclomol In ALS

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced that it has filed a response with the U.S. Food and Drug Administration (FDA) addressing issues cited by the FDA in its decision to place a clinical hold on the Company’s Phase IIb clinical trial with arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

More: continued here

Filed under: Muscular Dystrophy on April 2nd, 2008